We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App





Chembio Diagnostics Showcases New DPP Line of Rapid Tests at MEDICA 2019

By LabMedica International staff writers
Posted on 19 Nov 2019
Print article
Image: DPP® Syphilis Screen & Confirm Assay (Photo courtesy of Chembio Diagnostics)
Image: DPP® Syphilis Screen & Confirm Assay (Photo courtesy of Chembio Diagnostics)
Chembio Diagnostics (Medford, NY, USA) showcased its new DPP line of rapid tests, including DPP Syphilis Screen and Confirm; DPP HIV 1-2 Screen; and, for the global market, DPP Syphilis/HIV combo, the MEDICA 2019 International Trade Fair on November 18-21 in Düsseldorf, Germany. In addition, the company presented its legacy product line of HIV 1-2 SURE CHECK, HIV 1-2 STAT-PAK, HIV 1-2 STAT-PAK Dipstick, as well as its line of unique animal TB diagnostic products.

The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. The event drew over 6,000 exhibitors from 70 countries and 120,000 trade visitors from over 170 countries.

Chembio is a leading Point-of-Care (POC) diagnostics company that focuses on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

At the 2019 edition of MEDICA, Chembio showcased its DPP Syphilis Screen and Confirm Assay (CE Marked), a rapid POC test that simultaneously and separately detects treponemal and nontreponemal antibodies. Since it screens and confirms syphilis infection simultaneously, there is no need for reflex testing and it does not require specialized medical training. It provides results in as little as 15 minutes, enabling physicians to make treatment decisions, while reducing overtreatment rate and cost burden by eliminating repeated visits to healthcare professionals.

Chembio also showcased its DPP HIV 1-2 Screen Assay, a CLIA-waived test for the rapid detection of HIV 1 and HIV 2 antibodies in oral fluid and all blood matrices. It is intended for use as a POC test to aid in the diagnosis of infection with HIV 1 and HIV 2 and is suitable for use in multi-test algorithms that have been established in many countries or as a standalone initial test. For the global market, Chembio showcased its DPP Syphilis/HIV Combo Assay, the first dual HIV 1/2 and Syphilis POC test based on its DPP technology platform. It is a single-use, immunochromatographic, rapid test for the detection of antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV 1/2) and Treponema pallidum (the causative agent of syphilis) in fingerstick whole blood, venous whole blood, serum, and plasma. A unique feature of this kit is Chembio’s new DPP SampleTainer bottle which contains a pre-measured dilution buffer within a closed vial that also serves as a dropper for performing the assay.

In addition, Chembio showcased its legacy product line, including HIV 1-2 SURE CHECK, a unique, easy-to-use, self-contained, single-use collection and testing device for the rapid, visual detection of antibodies to HIV 1 and HIV 2; HIV 1-2 STAT-PAK, which are easy-to-perform, single-use diagnostic tests for the rapid (15 minutes), visual detection of antibodies to HIV 1 and HIV 2 at POC; and HIV 1-2 STAT-PAK Dipstick, which are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of antibodies to HIV 1 and HIV 2.

Related Links:
Chembio Diagnostics

New
Gold Supplier
CLIA Processor
VIRCLIA
New
Laboratory QC Software
Qualis Interlab
New
Parvovirus B19 IgG Immunoassay
AESKULISA Parvovirus B19 IgG
New
PCR Automatic Hybridization System
HybriSpot 12 Auto

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: The new assay enables accurate prognosis and detection data for those prone to esophageal cancer (Photo courtesy of Previse)

First-of-Its-Kind Test Helps Determine Future Risk of Esophageal Cancer

Esophageal cancer is among the most lethal cancers in the world and has a 20% five-year survival rate post-diagnosis. Barrett's esophagus is the sole precursor known and is a significant risk factor for... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Sampling a single stool using multiple PCR panels can identify more pathogens rapidly (Photo courtesy of Pexels)

PCR Panels for Acute GI Infections Can Lower Costs, Hospitalization and Antibiotic Use

Acute gastroenteritis impacts adults across all age groups and incurs enormous healthcare expenses. Now, a new study comprising 40,000 hospital visits across various geographic locations has revealed that... Read more

Pathology

view channel
Image: Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds (Photo courtesy of Michigan Medicine)

AI-Based Diagnostic Screening System Predicts Genetics of Cancerous Brain Tumors in 90 Seconds

The diagnosis and treatment of gliomas increasingly rely on molecular classification, as surgical benefits and risks vary depending on a patient's genetic makeup. Complete removal of the tumor can extend... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.